PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Ovintiv Inc. (OVV)
40.910.33 (-0.80%)
40.40 - 41.05
29.80 - 47.18
2.12M / 3.66M (Avg.)
18.02 | 2.27
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-26.90%
Negative revenue growth while CVE stands at 8.25%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
-35.05%
Negative gross profit growth while CVE is at 4.97%. Joel Greenblatt would examine cost competitiveness or demand decline.
507.34%
EBIT growth above 1.5x CVE's 115.41%. David Dodd would confirm if core operations or niche positioning yield superior profitability.
507.34%
Operating income growth above 1.5x CVE's 115.41%. David Dodd would confirm if consistent cost or pricing advantages drive this outperformance.
104.88%
Net income growth above 1.5x CVE's 60.15%. David Dodd would check if a unique moat or cost structure secures superior bottom-line gains.
105.99%
EPS growth above 1.5x CVE's 60.00%. David Dodd would review if superior product economics or effective buybacks drive the outperformance.
105.99%
Diluted EPS growth above 1.5x CVE's 60.00%. David Dodd would see if there's a robust moat protecting these shareholder gains.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-44.41%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
-515.70%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
198.69%
10Y revenue/share CAGR above 1.5x CVE's 70.23%. David Dodd would confirm if management’s strategic vision consistently outperforms the competitor.
-57.10%
Negative 5Y CAGR while CVE stands at 70.23%. Joel Greenblatt would push for a turnaround plan or reevaluation of the company’s product line.
-60.21%
Negative 3Y CAGR while CVE stands at 70.23%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
521.16%
Positive long-term OCF/share growth while CVE is negative. John Neff would see a structural advantage in sustained cash generation.
-61.07%
Both show negative mid-term OCF/share growth. Martin Whitman might suspect a challenged environment or large capital demands for both.
-65.65%
Both face negative short-term OCF/share growth. Martin Whitman would suspect macro or cyclical issues hitting them both.
-83.99%
Both face negative decade-long net income/share CAGR. Martin Whitman would suspect a shrinking or highly disrupted sector.
-97.09%
Both exhibit negative net income/share growth over five years. Martin Whitman would suspect a challenging environment for the entire niche.
-98.73%
Both companies show negative 3Y net income/share growth. Martin Whitman suspects macro or sector-specific headwinds in the short run.
264.25%
Equity/share CAGR of 264.25% while CVE is zero. Bruce Berkowitz might see a slight advantage that can compound significantly over 10 years.
-39.66%
Negative 5Y equity/share growth while CVE is at 0.00%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.
-63.04%
Negative 3Y equity/share growth while CVE is at 0.00%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
917.44%
Dividend/share CAGR of 917.44% while CVE is zero. Bruce Berkowitz sees a slight advantage in stepping up payouts steadily.
15.72%
Dividend/share CAGR of 15.72% while CVE is zero. Bruce Berkowitz sees a minor advantage in stepping up distributions, even modestly.
-50.06%
Negative near-term dividend growth while CVE invests at 0.00%. Joel Greenblatt sees a weaker short-term distribution policy unless justified by strategic spending.
-2.77%
Both reduce receivables yoy. Martin Whitman suspects a shift in the entire niche’s credit approach or softer demand.
-100.00%
Inventory is declining while CVE stands at 1.39%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
-31.54%
Negative asset growth while CVE invests at 1.11%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-48.09%
We have a declining book value while CVE shows 3.04%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
-5.08%
We’re deleveraging while CVE stands at 1.49%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.